Systemic immune-inflammation index predicts the clinical outcome in patients with nasopharyngeal carcinoma: a propensity score-matched analysis

Abstract

Systemic immune-inflammation index (SII), based on peripheral lymphocyte, neutrophil, and platelet counts, was recently investigated as a prognostic marker in several tumors. However, SII has not been reported in nasopharyngeal carcinoma (NPC). We evaluated the prognostic value of the SII in 327 patients with NPC. Univariate and multivariate analyses were calculated by the Cox proportional hazards regression model. The time-dependent receiver operating characteristics (ROC) curve was used to compare the discrimination ability for OS. PSM (propensity score matching) was carried out to imbalance the baseline characteristics. Our results showed that SII, PLR, NLR and MLR were all associated with OS in NPC patients in the Kaplan-Meier survival analysis. SII (HR: 2.26; 95% CI: 1.40-3.66; P=0.001), NLR (HR: 1.66; 95% CI: 1.08-2.53; P=0.020), and MLR (HR: 1.99; 95% CI: 1.17-3.39; P=0.011) were identified to be the independent prognostic factors. The AUC for SII was bigger than NLR, PLR and MLR for predicting survival in patients with NPC in 3 or 5-years. In the PSM analysis, SII remained an independent predictor for OS in NPC patients (HR=2.08, CI 1.22-3.55, P=0.007). SII is a novel, simple and inexpensive prognostic predictor for patients with NPC. The prognostic value of SII is superior to PLR, NLR and MLR.

Prognostic value of inflammation-based prognostic index in patients with nasopharyngeal carcinoma: a propensity score matching study

“… 14 , 16 , 17 On the other hand, we only found one study that reported the prognostic value of SII in NPC patients to date. 15 Although our study showed consistent result, some limitations were identified in these past studies that we believed might impede the reliability of these parameters as prognostic indicators in NPC. Some notable shortcomings were diverse radiotherapy techniques used, limited clinical endpoints adopted, and relatively smaller patient population compared to ours.…”

Low Skeletal Muscle Mass Impairs Quality of Life in Nasopharyngeal Carcinoma Patients Treated With Concurrent Chemoradiotherapy

“…Plasma Epstein-Barr virus DNA levels (copies/mL) were measured using a real-time quantitative polymerase chain reaction assay, and its cutoff value classified as previously described (16,17). Representative hematological biomarkers, such as the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to lymphocyte ratio (MLR), and prognostic nutritional index (PNI) were assessed, and their cutoffs classified as previously described (18)(19)(20). All patients were observed from fraction 15th to 30th of radiotherapy for 3 weeks.…”

<p>High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab</p>

“…The NLR and PLR have been widely used to predict the prognosis in various cancers, [6][7][8][9][10][11] and the SII has recently been determined to be an independent prognostic factor in many kinds of cancers. [22][23][24][25][26][27][28][29] These inflammation-based indexes, however, have rarely been investigated simultaneously in HER2-positive breast cancer. To the best of our knowledge, the current study is the first to comprehensively investigate and compare the prognostic values of these inflammation-based indexes in Chinese population with HER2-positive breast cancer who received scheduled adjuvant trastuzumab.…”

“…21 The systemic immune-inflammation index (SII), which is a parameter integrates neutrophils, platelets and lymphocytes, has recently been assessed in various solid cancers: colorectal cancer, nasopharyngeal cancer, hepatocellular cancer, pancreatic cancer, gastric cancer and prostate cancer. [22][23][24][25][26][27][28][29] A recent study evaluated the prognostic significance of SII in hormone receptor (HR)-negative, HER2positive breast cancer, and showed that an increased SII independently predicted poor survival for HER2-positive breast cancer patients. 30 In this study, the median DFS rates of 15.1 and 31.5 months in high and low SII patients, respectively, indicated that the included patients were at an extremely high risk, as in the BCIRG006 trial, the 10-year DFS rate was as high as 75% in the general population.…”